3 results
Primary:To evaluate the effects of 15 mg E4/3 mg DRSP, of 30 mcg EE/150 mcg LNG, and of 20 mcg EE/3 mg DRSP on hemostasis, endocrine function and lipid and carbohydrate metabolism parameters during 6 treatment cycles.Secondary:To assess the safety…
Objectives:To assess the safety of transitioning subjects to Raptiva therapy from standard oral systemic or phototherapy by overlapping with Raptiva whilst tapering the initial systemic therapy or phototherapy dose. The secondary objective is to…
Primary:• To determine the safety and tolerability of FHD-286 when administered as an oral monotherapy in subjects with metastatic uveal melanoma (UM)• To identify the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D) of FHD-…